Ken Griffin Axsome Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 138,800 shares of AXSM stock, worth $12.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

138,800

Previous 81,500 70.31%

Holding current value

$12.9 Million

Previous $6.56 Million 90.11%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$78.93 - $95.84 $35.4 Million - $43 Million	-448,555 Reduced 59.55%	304,682 $27.4 Million
Q2 2024 Aug 14, 2024	SELL	$65.72 - $80.5 $25.7 Million - $31.4 Million	-390,407 Reduced 34.14%	753,237 $60.6 Million
Q1 2024 May 15, 2024	BUY	$69.39 - $97.64 $3.79 Million - $5.33 Million	54,559 Added 5.01%	1,143,644 $91.3 Million
Q4 2023 Feb 14, 2024	SELL	$57.42 - $83.61 $11.9 Million - $17.3 Million	-206,539 Reduced 15.94%	1,089,085 $86.7 Million
Q3 2023 Nov 14, 2023	BUY	$69.25 - $82.21 $58.3 Million - $69.2 Million	841,306 Added 185.18%	1,295,624 $90.6 Million
Q2 2023 Aug 14, 2023	BUY	$58.41 - $90.35 $14.9 Million - $23.1 Million	255,297 Added 128.28%	454,318 $32.6 Million
Q1 2023 May 15, 2023	SELL	$58.39 - $75.0 $9.62 Million - $12.4 Million	-164,720 Reduced 45.28%	199,021 $12.3 Million
Q4 2022 Feb 14, 2023	SELL	$39.94 - $79.72 $6.69 Million - $13.4 Million	-167,596 Reduced 31.54%	363,741 $28.1 Million
Q3 2022 Nov 14, 2022	BUY	$36.06 - $69.85 $2.9 Million - $5.61 Million	80,342 Added 17.81%	531,337 $23.7 Million
Q2 2022 Aug 15, 2022	BUY	$21.74 - $46.75 $4.65 Million - $10 Million	213,982 Added 90.28%	450,995 $17.3 Million
Q1 2022 May 16, 2022	SELL	$23.7 - $41.39 $1.69 Million - $2.95 Million	-71,278 Reduced 23.12%	237,013 $9.81 Million
Q4 2021 Feb 14, 2022	BUY	$30.7 - $43.36 $6,876 - $9,712	224 Added 0.07%	308,291 $11.6 Million
Q3 2021 Nov 15, 2021	SELL	$19.91 - $68.26 $5.21 Million - $17.9 Million	-261,738 Reduced 45.93%	308,067 $10.2 Million
Q2 2021 Aug 16, 2021	BUY	$50.63 - $73.5 $8.13 Million - $11.8 Million	160,511 Added 39.22%	569,805 $38.4 Million
Q1 2021 May 17, 2021	SELL	$55.91 - $81.44 $17.6 Million - $25.6 Million	-314,845 Reduced 43.48%	409,294 $23.2 Million
Q4 2020 Feb 16, 2021	BUY	$66.31 - $86.52 $32.6 Million - $42.6 Million	492,133 Added 212.12%	724,139 $59 Million
Q3 2020 Nov 16, 2020	SELL	$68.34 - $85.84 $15.4 Million - $19.3 Million	-225,068 Reduced 49.24%	232,006 $16.5 Million
Q2 2020 Aug 14, 2020	SELL	$49.87 - $98.69 $15.3 Million - $30.2 Million	-306,420 Reduced 40.13%	457,074 $37.6 Million
Q1 2020 May 15, 2020	BUY	$41.2 - $101.31 $7.66 Million - $18.8 Million	185,851 Added 32.17%	763,494 $44.9 Million
Q4 2019 Feb 14, 2020	BUY	$16.71 - $106.24 $7.58 Million - $48.2 Million	453,636 Added 365.81%	577,643 $59.7 Million
Q3 2019 Nov 14, 2019	BUY	$20.24 - $29.16 $1.67 Million - $2.4 Million	82,473 Added 198.57%	124,007 $2.51 Million
Q2 2019 Aug 14, 2019	BUY	$13.46 - $25.75 $111,152 - $212,643	8,258 Added 24.82%	41,534 $1.07 Million
Q1 2019 May 15, 2019	BUY	$2.63 - $16.34 $46,537 - $289,136	17,695 Added 113.57%	33,276 $0
Q2 2018 Aug 10, 2018	BUY	$2.15 - $3.6 $33,499 - $56,091	15,581 New	15,581 $0

Others Institutions Holding AXSM

# of Institutions

326

Shares Held

37.7M

Call Options Held

912K

Put Options Held

855K

View Full List

About Axsome Therapeutics, Inc.

Ticker AXSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,878,000
Market Cap $3.99B
Description
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...

More about AXSM

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account